Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 52.72 -0.49% -0.26
ICPT closed down 0.49 percent on Wednesday, January 17, 2018, on approximately normal volume. The bears made the stock sink to a new 52-week low. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ICPT trend table...

Date Alert Name Type % Chg
Jan 17 New 52 Week Closing Low Bearish 0.00%
Jan 17 Hammer Candlestick Bullish 0.00%
Jan 17 New 52 Week Low Weakness 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 New 52 Week Closing Low Bearish -0.49%
Jan 16 180 Bearish Setup Bearish Swing Setup -0.49%
Jan 16 Outside Day Range Expansion -0.49%
Jan 16 Wide Bands Range Expansion -0.49%
Jan 16 Oversold Stochastic Weakness -0.49%

Older signals for ICPT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.
Is ICPT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 135.59
52 Week Low 51.53
Average Volume 718,694
200-Day Moving Average 93.3
50-Day Moving Average 60.1156
20-Day Moving Average 58.22
10-Day Moving Average 54.767
Average True Range 2.5823
ADX 24.87
+DI 11.97
-DI 29.07
Chandelier Exit (Long, 3 ATRs ) 58.2031
Chandelier Exit (Short, 3 ATRs ) 59.2769
Upper Bollinger Band 66.2048
Lower Bollinger Band 50.2352
Percent B (%b) 0.16
BandWidth 27.429749
MACD Line -2.286
MACD Signal Line -1.7839
MACD Histogram -0.5021
Fundamentals Value
Market Cap 1.32 Billion
Num Shares 25.1 Million
EPS -15.49
Price-to-Earnings (P/E) Ratio -3.40
Price-to-Sales 20.99
Price-to-Book 8.77
PEG Ratio -0.61
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 55.27
Resistance 3 (R3) 55.16 54.19 54.85
Resistance 2 (R2) 54.19 53.54 54.25 54.70
Resistance 1 (R1) 53.46 53.14 52.98 53.57 54.56
Pivot Point 52.49 52.49 52.25 52.55 52.49
Support 1 (S1) 51.76 51.84 51.28 51.87 50.88
Support 2 (S2) 50.79 51.44 50.85 50.74
Support 3 (S3) 50.06 50.79 50.60
Support 4 (S4) 50.17